IHC staining of tumor sections with an anti-CD8 antibody showed a marked increase of CD8+ T cells in 5-FU/oxaliplatin or 5-FU/oxaliplatin/anti-PD-1-treated tumors as compared to control or anti-PD-1-treated tumors (Figure 5D, left panel). Here, CD8A is linked to neoplasm.